Finance

Merck is acquiring Terns Pharmaceuticals for $6.7 billion to bolster its oncology pipeline, while Shionogi is set to purchase 50% of Apnimed's ownership of SASS.

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research collaboration with Merck to discover novel drug targets in inflammatory bowel disease, and Gilead Sciences agrees to acquire privately held Ouro Medicines in a deal valued at up to $2.18 billion.

Inclusive Capital Partners sold a stake worth about 0.9 % of the company.

Pfizer urges shareholders to reject an unsolicited mini-tender offer from Tutanota LLC, who is seeking to purchase up to 1 million Pfizer shares at $32.00-per-share.

The funding rounds are part of a broader effort to advance next-generation T-cell engager platforms targeting cancers.

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics, factors that favor strategically driven growth pursuits ahead.

Cognito Therapeutics and NexCure have each closed new funding rounds this week, advancing an at-home Alzheimer's stimulation device and a platform to bring CAR-T therapy to community settings

Teva Pharmaceuticals has secured $400 million from Blackstone Life Sciences to advance duvakitug, an experimental monoclonal antibody in Phase III trials for ulcerative colitis and Crohn's disease.

Novo Nordisk is investing to expand its Athlone, Ireland facility, aiming to boost global manufacturing capacity for oral GLP-1 treatments.

Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.

Three key takeaways from the JPM industry reset offer clear clues to how biopharma companies—and leaders—must adapt to stand out and ultimately thrive in 2026.

Special Guest Op-Ed: What a decade of collaboration and shared effort reveals about the future of drug development.

QuantX Biosciences and Pandorum Technologies have closed new Series B financing rounds, raising $85 million and $18 million respectively, to advance their platform-driven approaches.

The EY deals leader discusses recent findings and trends from 2025.

Novo Nordisk posted strong 2025 sales growth driven by obesity treatments and U.S. market performance, but tempered operating profits signal a more cautious outlook for 2026.

Novartis reported solid full-year growth and margin expansion in 2025, but also set the stage for a challenging year ahead marked by major patent expirations.

The facility builds on Eli Lilly's $50 Billion investment strategy to strengthen the company's domestic manufacturing capabilities.

Shionogi and GSK are streamlining ViiV Healthcare’s ownership by buying out Pfizer’s 11.7% stake, leaving the HIV specialist jointly owned by its two long-time partners.

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical companies entered 2026 by raising list prices on hundreds of brand-name medicines, underscoring the limited impact of recent policy efforts on the broader U.S. drug pricing landscape.

Financing announcements across the pharma sector reflect the industry’s continued interest in advancing clinical-stage programs across genetic medicine, immunology, and chronic diseases.

Clarivate’s Drugs to Watch 2026 report highlights Eli Lilly’s late-stage cardiometabolic candidates orforglipron and retatrutide as the clear standouts in an obesity and diabetes market projected to reach $150 billion by 2035.

AstraZeneca’s exclusive global licensing deal for Jacobio’s pan-KRAS inhibitor JAB-23E73 underscores a renewed industry push of one of oncology’s most elusive targets.

Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target disease-driving mutations with the aim of delivering more precise and durable treatments.

As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.

Pfizer’s shares slid after the company outlined its 2026 revenue and EPS guidance, reflecting investor unease over declining Covid-19 sales, looming patent expirations, and a capital allocation strategy that prioritizes pipeline investment over buybacks during a pivotal post-LOE transition period.